Scrip RSS Feedhttps://insights.citeline.comThe Latest News & Analysis from ScripSat, 13 Jun 2026 04:10:56 +0000en1hourly1 https://insights.citeline.com/scrip/business/financing/finance-watch/finance-watch-biopharma-ipos-on-the-upswing-including-ex-us-offerings-GIROY5PMSNDDHLUNV4MZRBIGJA/<![CDATA[Finance Watch: Biopharma IPOs On The Upswing, Including Ex-US Offerings]]>premium

      
]]> https://feeds.feedblitz.com/~/957994394/0/scrip~Finance-Watch-Biopharma-IPOs-On-The-Upswing-Including-ExUS-Offerings/https://insights.citeline.com/scrip/business/financing/finance-watch/finance-watch-biopharma-ipos-on-the-upswing-including-ex-us-offerings-GIROY5PMSNDDHLUNV4MZRBIGJA/
      
]]> Fri, 12 Jun 2026 21:48:12 +0000 https://insights.citeline.com/scrip/conferences/asco/astrazeneca-builds-up-oncology-as-it-looks-to-2030-7LLNN5VGIJE6TF6JC3PWCLLBHQ/<![CDATA[AstraZeneca Builds Up Oncology As It Looks To 2030 ]]>premium

      
]]> https://feeds.feedblitz.com/~/957994397/0/scrip~AstraZeneca-Builds-Up-Oncology-As-It-Looks-To/https://insights.citeline.com/scrip/conferences/asco/astrazeneca-builds-up-oncology-as-it-looks-to-2030-7LLNN5VGIJE6TF6JC3PWCLLBHQ/
      
]]> Fri, 12 Jun 2026 21:47:06 +0000Alaric DeArment https://insights.citeline.com/scrip/r-and-d/clinical-trials/jazzs-zepzelca-fails-another-second-line-sclc-trial-2I6B3AJJHVH23PZWX4IXAS3ZCI/<![CDATA[Jazz’s Zepzelca Fails Another Second-Line SCLC Trial]]>premium

      
]]> https://feeds.feedblitz.com/~/957992423/0/scrip~Jazz%e2%80%99s-Zepzelca-Fails-Another-SecondLine-SCLC-Trial/https://insights.citeline.com/scrip/r-and-d/clinical-trials/jazzs-zepzelca-fails-another-second-line-sclc-trial-2I6B3AJJHVH23PZWX4IXAS3ZCI/
      
]]> Fri, 12 Jun 2026 20:02:41 +0000 https://insights.citeline.com/scrip/conferences/asco/pfizers-legos-lays-out-oncology-focus-and-direction-S3AH5WALQBFBPK76HATREZDOHY/<![CDATA[Pfizer’s Legos Lays Out Oncology Focus And Direction]]>premium

      
]]> https://feeds.feedblitz.com/~/957992153/0/scrip~Pfizer%e2%80%99s-Legos-Lays-Out-Oncology-Focus-And-Direction/https://insights.citeline.com/scrip/conferences/asco/pfizers-legos-lays-out-oncology-focus-and-direction-S3AH5WALQBFBPK76HATREZDOHY/
      
]]> Fri, 12 Jun 2026 19:48:59 +0000 https://insights.citeline.com/scrip/therapeutic-category/musculoskeletal/eular-levicept-believes-it-has-the-new-humira-on-its-hands-V2E3GC3WAVD5JMUPVWXI7RHAQQ/<![CDATA[EULAR: Levicept Believes It Has The New Humira On Its Hands]]>premium

      
]]> https://feeds.feedblitz.com/~/957983486/0/scrip~EULAR-Levicept-Believes-It-Has-The-New-Humira-On-Its-Hands/https://insights.citeline.com/scrip/therapeutic-category/musculoskeletal/eular-levicept-believes-it-has-the-new-humira-on-its-hands-V2E3GC3WAVD5JMUPVWXI7RHAQQ/
      
]]> Fri, 12 Jun 2026 14:33:06 +0000 https://insights.citeline.com/scrip/r-and-d/pipeline-watch/pipeline-watch-fourteen-approvals-and-ten-phase-iii-readouts-VXK33A7XWFDABPK3QD2IKG5AZM/<![CDATA[Pipeline Watch: Fourteen Approvals And Ten Phase III Readouts]]>premium

      
]]> https://feeds.feedblitz.com/~/957985271/0/scrip~Pipeline-Watch-Fourteen-Approvals-And-Ten-Phase-III-Readouts/https://insights.citeline.com/scrip/r-and-d/pipeline-watch/pipeline-watch-fourteen-approvals-and-ten-phase-iii-readouts-VXK33A7XWFDABPK3QD2IKG5AZM/
      
]]> Fri, 12 Jun 2026 15:09:12 +0000 https://insights.citeline.com/scrip/market-intelligence/top-drugs/top-10-drugs-q1-2026-new-sheriff-in-town-as-mounjaro-unseats-keytruda-MT33WZJRPJHOPCFITFRLRMKJAA/<![CDATA[Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda]]>premium

      
]]> https://feeds.feedblitz.com/~/957982391/0/scrip~Top-Drugs-Q-New-Sheriff-In-Town-As-Mounjaro-Unseats-Keytruda/https://insights.citeline.com/scrip/market-intelligence/top-drugs/top-10-drugs-q1-2026-new-sheriff-in-town-as-mounjaro-unseats-keytruda-MT33WZJRPJHOPCFITFRLRMKJAA/
      
]]> Fri, 12 Jun 2026 13:56:12 +0000 https://insights.citeline.com/scrip/market-access/why-big-pharma-should-pay-attention-to-glp-1-drug-use-insights-from-brazil-MFFTMWH4T5GGLC7ZHK7NQAPICY/<![CDATA[Why Big Pharma Should Pay Attention To GLP-1 Drug Use Insights From Brazil]]>premium

      
]]> https://feeds.feedblitz.com/~/957974924/0/scrip~Why-Big-Pharma-Should-Pay-Attention-To-GLP-Drug-Use-Insights-From-Brazil/https://insights.citeline.com/scrip/market-access/why-big-pharma-should-pay-attention-to-glp-1-drug-use-insights-from-brazil-MFFTMWH4T5GGLC7ZHK7NQAPICY/
      
]]> Fri, 12 Jun 2026 09:10:27 +0000 https://insights.citeline.com/scrip/focus-on-asia/india/us-drug-shortages-ease-but-discontinuations-surge-asia-supply-chain-risks-run-deep-QTQCO6KNOBG25HXMVNV5HX5NM4/<![CDATA[US Drug Shortages Ease But Discontinuations Surge, Asia Supply Chain Risks Run Deep]]>premium

      
]]> https://feeds.feedblitz.com/~/957951839/0/scrip~US-Drug-Shortages-Ease-But-Discontinuations-Surge-Asia-Supply-Chain-Risks-Run-Deep/https://insights.citeline.com/scrip/focus-on-asia/india/us-drug-shortages-ease-but-discontinuations-surge-asia-supply-chain-risks-run-deep-QTQCO6KNOBG25HXMVNV5HX5NM4/
      
]]> Thu, 11 Jun 2026 13:16:16 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/longbios-antibody-hits-phase-iii-endpoint-in-seasonal-allergic-rhinitis-OPUVHUVO4ZAPXHDYIRXOEKKDPI/<![CDATA[LongBio’s Antibody Hits Phase III Endpoint In Seasonal Allergic Rhinitis]]>premium

      
]]> https://feeds.feedblitz.com/~/957975263/0/scrip~LongBio%e2%80%99s-Antibody-Hits-Phase-III-Endpoint-In-Seasonal-Allergic-Rhinitis/https://insights.citeline.com/scrip/r-and-d/clinical-trials/longbios-antibody-hits-phase-iii-endpoint-in-seasonal-allergic-rhinitis-OPUVHUVO4ZAPXHDYIRXOEKKDPI/
      
]]> Fri, 12 Jun 2026 09:14:32 +0000 https://insights.citeline.com/scrip/womens-health/ambitious-oriva-wants-to-be-key-player-in-womens-health-PXMPBTKPWZGEJIKHCOYE4CVMFU/<![CDATA[Ambitious Oriva Wants To Be Key Player In Women’s Health]]>premium

      
]]> https://feeds.feedblitz.com/~/957945317/0/scrip~Ambitious-Oriva-Wants-To-Be-Key-Player-In-Women%e2%80%99s-Health/https://insights.citeline.com/scrip/womens-health/ambitious-oriva-wants-to-be-key-player-in-womens-health-PXMPBTKPWZGEJIKHCOYE4CVMFU/
      
]]> Thu, 11 Jun 2026 08:31:16 +0000 https://insights.citeline.com/scrip/business/deals/orionis-back-in-novartiss-orbit-with-new-molecular-glue-deal-LK6BL4WS7VHMHKKVEOOEGFXVOU/<![CDATA[Orionis Back In Novartis’s Orbit With New Molecular Glue Deal]]>premium

      
]]> https://feeds.feedblitz.com/~/957950810/0/scrip~Orionis-Back-In-Novartis%e2%80%99s-Orbit-With-New-Molecular-Glue-Deal/https://insights.citeline.com/scrip/business/deals/orionis-back-in-novartiss-orbit-with-new-molecular-glue-deal-LK6BL4WS7VHMHKKVEOOEGFXVOU/
      
]]> Thu, 11 Jun 2026 12:45:57 +0000 https://insights.citeline.com/scrip/leadership/executives-on-the-move/executives-on-the-move-four-ceos-and-five-cfos-among-this-weeks-changes-6R62ZXJZLNBO7OZIKTMCKI3EZA/<![CDATA[Executives On The Move: Four CEOs And Five CFOs Among This Week’s Changes]]>premium

      
]]> https://feeds.feedblitz.com/~/957953630/0/scrip~Executives-On-The-Move-Four-CEOs-And-Five-CFOs-Among-This-Week%e2%80%99s-Changes/https://insights.citeline.com/scrip/leadership/executives-on-the-move/executives-on-the-move-four-ceos-and-five-cfos-among-this-weeks-changes-6R62ZXJZLNBO7OZIKTMCKI3EZA/
      
]]> Thu, 11 Jun 2026 14:04:18 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/positive-del-brax-biomarker-data-offers-early-support-for-novartiss-avidity-bet-EZGLCIXAMRDAXCK4NYYSO7AJEA/<![CDATA[Positive Del-Brax Biomarker Data Offers Early Support For Novartis’s Avidity Bet]]>premium

      
]]> https://feeds.feedblitz.com/~/957951287/0/scrip~Positive-DelBrax-Biomarker-Data-Offers-Early-Support-For-Novartis%e2%80%99s-Avidity-Bet/https://insights.citeline.com/scrip/r-and-d/clinical-trials/positive-del-brax-biomarker-data-offers-early-support-for-novartiss-avidity-bet-EZGLCIXAMRDAXCK4NYYSO7AJEA/
      
]]> Thu, 11 Jun 2026 12:56:06 +0000 https://insights.citeline.com/scrip/therapeutic-category/alimentary-metabolic/ada-2026-roche-still-looking-for-ways-to-stand-out-in-obesity-YWTKKJKX6FEVXDLTBNPRR6MD6E/<![CDATA[ADA 2026: Roche Still Looking For Ways To Stand Out In Obesity]]>premium

      
]]> https://feeds.feedblitz.com/~/957957755/0/scrip~ADA-Roche-Still-Looking-For-Ways-To-Stand-Out-In-Obesity/https://insights.citeline.com/scrip/therapeutic-category/alimentary-metabolic/ada-2026-roche-still-looking-for-ways-to-stand-out-in-obesity-YWTKKJKX6FEVXDLTBNPRR6MD6E/
      
]]> Thu, 11 Jun 2026 16:18:44 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/jjs-imaavy-goes-two-for-two-with-pivotal-trial-success-in-waiha-UITFMCFSQ5EM7ALKZRLH73MBZU/<![CDATA[J&J’s Imaavy Goes Two-For-Two With Pivotal Trial Success In wAIHA]]>premium

      
]]> https://feeds.feedblitz.com/~/957962528/0/scrip~JJ%e2%80%99s-Imaavy-Goes-TwoForTwo-With-Pivotal-Trial-Success-In-wAIHA/https://insights.citeline.com/scrip/r-and-d/clinical-trials/jjs-imaavy-goes-two-for-two-with-pivotal-trial-success-in-waiha-UITFMCFSQ5EM7ALKZRLH73MBZU/
      
]]> Thu, 11 Jun 2026 20:12:31 +0000 https://insights.citeline.com/scrip/therapeutic-category/immunological/takedas-zasocitinib-beats-bmss-sotyktu-in-moderate-to-severe-plaque-psoriasis-H4TOXXIVZVCTVG3ZAQ7XP5UBL4/<![CDATA[Takeda’s Zasocitinib Beats BMS’s Sotyktu In Moderate-To-Severe Plaque Psoriasis]]>premium

      
]]> https://feeds.feedblitz.com/~/957962165/0/scrip~Takeda%e2%80%99s-Zasocitinib-Beats-BMS%e2%80%99s-Sotyktu-In-ModerateToSevere-Plaque-Psoriasis/https://insights.citeline.com/scrip/therapeutic-category/immunological/takedas-zasocitinib-beats-bmss-sotyktu-in-moderate-to-severe-plaque-psoriasis-H4TOXXIVZVCTVG3ZAQ7XP5UBL4/
      
]]> Thu, 11 Jun 2026 20:02:28 +0000 https://insights.citeline.com/scrip/therapeutic-category/anticancer/enlivens-updated-cml-data-may-be-competitive-versus-scemblix-S46DYRV3W5HP3OUGKHGI4VHFZE/<![CDATA[Enliven’s Updated CML Data May Be Competitive Versus Scemblix]]>premium

      
]]> https://feeds.feedblitz.com/~/957963599/0/scrip~Enliven%e2%80%99s-Updated-CML-Data-May-Be-Competitive-Versus-Scemblix/https://insights.citeline.com/scrip/therapeutic-category/anticancer/enlivens-updated-cml-data-may-be-competitive-versus-scemblix-S46DYRV3W5HP3OUGKHGI4VHFZE/
      
]]> Thu, 11 Jun 2026 21:28:27 +0000 https://insights.citeline.com/scrip/partnered-content/insights-from-industry-leaders-on-chinas-rise-as-a-global-powerhouse-in-drug-innovation-2NVTPIHEPRDTRMPQQ6CCLCKS4E/<![CDATA[Insights from industry leaders on China’s rise as a global powerhouse in drug innovation]]>free

      
]]> https://feeds.feedblitz.com/~/957928553/0/scrip~Insights-from-industry-leaders-on-China%e2%80%99s-rise-as-a-global-powerhouse-in-drug-innovation/https://insights.citeline.com/scrip/partnered-content/insights-from-industry-leaders-on-chinas-rise-as-a-global-powerhouse-in-drug-innovation-2NVTPIHEPRDTRMPQQ6CCLCKS4E/
      
]]> Wed, 10 Jun 2026 16:09:08 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/sanofi-stops-phase-iii-mobilize-study-as-it-reviews-riliprubarts-cidp-program-LCKS7TYMNVF6PCLQST3G4T5OUE/<![CDATA[Sanofi Stops Phase III MOBILIZE Study As It Reviews Riliprubart’s CIDP Program]]>premium

      
]]> https://feeds.feedblitz.com/~/957923912/0/scrip~Sanofi-Stops-Phase-III-MOBILIZE-Study-As-It-Reviews-Riliprubart%e2%80%99s-CIDP-Program/https://insights.citeline.com/scrip/r-and-d/clinical-trials/sanofi-stops-phase-iii-mobilize-study-as-it-reviews-riliprubarts-cidp-program-LCKS7TYMNVF6PCLQST3G4T5OUE/
      
]]> Wed, 10 Jun 2026 13:45:25 +0000 https://insights.citeline.com/scrip/therapeutic-category/alimentary-metabolic/ada-2026-astrazeneca-to-move-fast-on-obesity-and-heart-pill-combinations-MVMM57BZ2BCEZOXGKBGYQNOHPQ/<![CDATA[ADA 2026: AstraZeneca To Move Fast On Obesity And Heart Pill Combinations]]>premium

      
]]> https://feeds.feedblitz.com/~/957929021/0/scrip~ADA-AstraZeneca-To-Move-Fast-On-Obesity-And-Heart-Pill-Combinations/https://insights.citeline.com/scrip/therapeutic-category/alimentary-metabolic/ada-2026-astrazeneca-to-move-fast-on-obesity-and-heart-pill-combinations-MVMM57BZ2BCEZOXGKBGYQNOHPQ/
      
]]> Wed, 10 Jun 2026 16:28:52 +0000 https://insights.citeline.com/scrip/conferences/asco/jj-opts-not-to-follow-the-oncology-crowd-SD42FARYPNDOLNGLOWTYQN65NY/<![CDATA[J&J Opts Not To Follow The Oncology Crowd ]]>premium

      
]]> https://feeds.feedblitz.com/~/957934883/0/scrip~JJ-Opts-Not-To-Follow-The-Oncology-Crowd/https://insights.citeline.com/scrip/conferences/asco/jj-opts-not-to-follow-the-oncology-crowd-SD42FARYPNDOLNGLOWTYQN65NY/
      
]]> Wed, 10 Jun 2026 21:13:22 +0000Alaric DeArment https://insights.citeline.com/scrip/business/financing/sonothera-raises-125m-to-advance-next-gen-dmd-gene-therapy-5WU47GUEMNCVFMKIR3ONRTR7VM/<![CDATA[SonoThera Raises $125m To Advance Next-Gen DMD Gene Therapy]]>premium

      
]]> https://feeds.feedblitz.com/~/957935279/0/scrip~SonoThera-Raises-m-To-Advance-NextGen-DMD-Gene-Therapy/https://insights.citeline.com/scrip/business/financing/sonothera-raises-125m-to-advance-next-gen-dmd-gene-therapy-5WU47GUEMNCVFMKIR3ONRTR7VM/
      
]]> Wed, 10 Jun 2026 21:28:35 +0000 https://insights.citeline.com/scrip/business/financing/parabilis-breaks-kaileras-short-lived-biopharma-ipo-record-QWQ6AWHH2BB7JDKDGHTVTLKT2E/<![CDATA[Parabilis Breaks Kailera’s Short-Lived Biopharma IPO Record]]>premium

      
]]> https://feeds.feedblitz.com/~/957935276/0/scrip~Parabilis-Breaks-Kailera%e2%80%99s-ShortLived-Biopharma-IPO-Record/https://insights.citeline.com/scrip/business/financing/parabilis-breaks-kaileras-short-lived-biopharma-ipo-record-QWQ6AWHH2BB7JDKDGHTVTLKT2E/
      
]]> Wed, 10 Jun 2026 21:33:35 +0000 https://insights.citeline.com/scrip/partnered-content/opportunities-and-best-practices-in-early-phase-research-54J6PLP7IBBGPCPJVX4DU7PRTM/<![CDATA[Opportunities and Best Practices in Early Phase Research]]>free

      
]]> https://feeds.feedblitz.com/~/957927590/0/scrip~Opportunities-and-Best-Practices-in-Early-Phase-Research/https://insights.citeline.com/scrip/partnered-content/opportunities-and-best-practices-in-early-phase-research-54J6PLP7IBBGPCPJVX4DU7PRTM/
      
]]> Wed, 10 Jun 2026 15:44:41 +0000